US20040057938A1 - Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin - Google Patents

Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin Download PDF

Info

Publication number
US20040057938A1
US20040057938A1 US10/665,188 US66518803A US2004057938A1 US 20040057938 A1 US20040057938 A1 US 20040057938A1 US 66518803 A US66518803 A US 66518803A US 2004057938 A1 US2004057938 A1 US 2004057938A1
Authority
US
United States
Prior art keywords
amniotic membrane
method
treatment
homogenate
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/665,188
Inventor
Emiliano Ghinelli
Original Assignee
Emiliano Ghinelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US41173802P priority Critical
Application filed by Emiliano Ghinelli filed Critical Emiliano Ghinelli
Priority to US10/665,188 priority patent/US20040057938A1/en
Publication of US20040057938A1 publication Critical patent/US20040057938A1/en
Priority claimed from US13/956,520 external-priority patent/US8738494B1/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs

Abstract

A method of preparing an amniotic membrane extract including the steps of obtaining a healthy amniotic membrane from a pregnant mammal, such as a pig, cow, horse or human, homogenizing the membrane to obtain a homogenate solution, freezing the homogenate solution, and lyophilizing the frozen homogenate solution to dryness is disclosed. Preferably, the lyophilized homogenate is pulverized to a powder. The lyophilized homogenate is then reconstituted before use, e.g., in a liquid, such as a balanced salt solution or fresh amniotic fluid, or in another substance, such a gel, an ointment, a cream or a soap, depending on the intended use. Also disclosed is a pharmaceutical composition prepared according to the method of the invention, for prophylaxis and/or treatment of a disease or condition, especially of the eye or the skin. Exemplary pharmaceutically acceptable carriers for the compositin of the invention include an ophthalmic solution for eye drops, a gel, an ointment, an emulsion, a cream, a powder and a spray.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims the priority of U.S. Provisional Application No. 60/411,738 filed Sep. 18, 2002 entitled, EXTRACT OF HUMAN AMNIOTIC MEMBRANE FOR TREATMENT OF OCCULAR INJURIES AND DISEASES, the whole of which is hereby incorporated by reference herein.[0001]
  • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • N/A [0002]
  • BACKGROUND OF THE INVENTION
  • Corneal epithelium integrity and corneal sensory innervation play a pivotal role in maintaining ocular surface health (Tseng et al., 1997). Clinical conditions leading to corneal nerve disruption associated with epithelial defects and persistent and progressive corneal ulcers include viral infections, autoimmune and endocrine diseases, thermal and chemical burns, multiple ocular surgeries and V pair ganglion or sensory routes affections (Donzis et al., 1987; Gould, 1967; Hyndiuk et al., 1977; and Liesegang, 1985). Current therapeutic strategies adopted for such conditions include medical therapy (e.g., tear substitutes, topical and systemic drugs), surgical approaches based on amniotic membrane transplantation (Chen et al., 2000), and, quite recently, a panacea of novel compounds, especially growth factors able to promote effectively corneal epithelial re-growth. These molecules, mainly neuropeptides, include epidermal growth factor (Kandarakis et al., 1984), aldose reductase inhibitors (Hosolani et al., 1995), insulin-like growth factor type I associated with Substance P, and nerve growth factor (Lambiase et al., 1998). In particular, amniotic membrane tissue has shown powerful and interesting properties in bringing about the anatomical recovery of the anterior ocular surface from a disease condition, along with observations regarding its composition that include even more growth factors than the list mentioned above (Uchida et al., 2000). Unfortunately, an improvement in the patient's visual outcome following application of amniotic membrane tissue is often unsuccessful (Solomon et al., 2002). Application of the amniotic membrane as a multilayer structure instead of as a monolayer has been somewhat more effective, which may be due to the quantity of amniotic membrane applied biological factors (Prabhasawat, 2001). Cryopreserved human amniotic membrane has been applied to the affected eye of a patient as a patch after defrosting (Kim et al., 1995). The applied patch released a restricted amount of factors to the damaged tissue, but the survival of the human amniotic membrane cells decreased to zero in a few days. [0003]
  • Despite the partial effectiveness of these approaches, these treatments are usually unable to completely restore the affected part, functionally and anatomically. Accordingly, a more effective and efficient approach in treating the symptoms and clinical conditions of ocular diseases and related conditions would be useful. [0004]
  • BRIEF SUMMARY OF THE INVENTION
  • These objectives are achieved using the compositions and methods according to the invention. In one aspect, the invention is directed to a method of preparing an amniotic membrane extract in which the method includes the steps of obtaining a healthy amniotic membrane from a pregnant mammal, such as a pig, cow, horse or human, homogenizing the membrane to obtain a homogenate solution, freezing the homogenate solution, and lyophilizing the frozen homogenate solution to dryness. Preferably, the lyophilized homogenate is pulverized to a powder. The lyophilized homogenate is then reconstituted before use, e.g., in a liquid, such as a balanced salt solution or fresh amniotic fluid, or in another substance, such a gel, an ointment, a cream or a soap, depending on the intended use. [0005]
  • In another aspect, the invention is directed to a pharmaceutical composition for prophylaxis and/or treatment of a disease or condition, the composition including a therapeutically effective amount of an amniotic membrane extract prepared according to the method of the invention and dispersed in a pharmaceutically acceptable carrier for administration to a patient. Exemplary pharmaceutically acceptable carriers include an ophthalmic solution for eye drops, a gel, an ointment, an emulsion, a cream, a powder and a spray. Furthermore, the amniotic membrane extract may be distributed on a bandage or a medicinal contact lens for local administration to a patient. [0006]
  • In a further aspect, the invention is directed to a method of prophylaxis and/or treatment of a disease or condition, the method including the steps of providing a patient in need of such prophylaxis and/or treatment, and administering an effective amount of the pharmaceutical composition of the invention to the patient. Exemplary diseases or conditions treatable by the method of the invention include persistent corneal ulcer, Ocular Cicatritial Pemphigoid, Stevens-Johnson syndrome, conjunctival inflammation, dry eye, Sjögren's syndrome, chemical or thermal injuries, multi-surgery effects, contact lenses over-wear, severe microbial infections, neurotrophic keratitis, ischemic keratitis, peripheral ulcerative or inflammatory keratitis, limbitis aniridia, pterigium or pseudopterigium, and multiple endocrine deficiency. For ocular use, the pharmaceutically acceptable carrier preferably includes preservative free eye drops. [0007]
  • In yet another aspect, the invention is directed to a kit that includes a therapeutically effective amount of an amniotic membrane extract prepared according to the method of the invention and instructions for the use thereof. Preferably, the kit further includes a pharmaceutically acceptable carrier for administering the amniotic membrane extract to a patient. The amniotic membrane extract according to the invention has the healing properties of amniotic membrane tissue, but at an enhanced level, and can be used according to the invention without the need for costly surgical procedures.[0008]
  • BRIEF DESCRIPTION OF THE FIGURES
  • Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof and from the claims, taken in conjunction with the accompanying figures, in which: [0009]
  • FIGS. 1A (white light) and [0010] 1B (UV light) are photographs showing the eye of a patient with Ocular Cicatritial Pemphigoid at day 0 (2.5× magnitude);
  • FIGS. 2A (white light) and [0011] 2B (UV light) are photographs showing the eye of the patient of FIGS. 1A and 1B at day 10 after treatment with the composition of the invention (2.5× magnitude);
  • FIGS. 3A (white light), [0012] 3B (UV light) and FIG. 3C (white light)are photographs showing the eye of the patient of FIGS. 1A and 1B at day 30 (FIGS. 3A and 3B) and day 40 (FIG. 3C) after further treatment with the composition of the invention (2.5× magnitude); and
  • FIGS. 4A and 4B depict photographs of a patient having enhanced wrinkling adjacent to the eye at day 0 (FIG. 4A) and day 14 (FIG. 4B) after treatment with the composition of the invention (1.5× magnitude). [0013]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The therapeutic composition of the invention comprises a healthy amniotic membrane extract derived from the amniotic membrane of a pregnant mammal, e.g., a human, a pig, a cow, or a horse. A healthy amniotic membrane is one that has been maintained under sterile conditions and that has been determined to be virus free, e.g., free from the hepatitis-B and C viruses and human immunodeficiency virus, and free from bacterial contamination. The amniotic membrane is, preferably, freshly obtained and quickly processed for preparation of the extract according to the invention, as described herein. The membrane may be stored prior to preparation of the extract. However, storage of the amniotic membrane tissue will result in some loss in cell viability. [0014]
  • The amniotic membrane extract according to the invention has the healing properties of amniotic membrane tissue, but at an enhanced level, and can be used according to the invention without the need for costly surgical procedures. The application of the therapeutic composition of the invention may be performed by a physician or by a capable patient at home. The composition is straightforward to prepare and may be constituted to contain any concentration of factors desired, depending on the severity of the disease or condition to be treated. The treatment may be administered as necessary without incurring undesirable side effects. [0015]
  • The composition of the invention is useful for treating ocular diseases and/or skin disorders and many other diseases when used in accordance with the method of the invention, as described herein. Ocular Cicatritial Pemphigliod (OCP), for example, is known to be a rare immunological related disease that involves the anterior ocular surface leading to blindness despite any kind of therapeutic approach (Foster, 1986). Therapeutic choices like anti-inflammatory drugs, steroids and immunosuppressive agents help to control the disease but very often are unable to block its natural progression. The natural history of OCP begins with recurrent conjunctival inflammations and then fibrosis, associated with fornix foreshortening, symblepharon and entropion, progressively leading to a dry eye syndrome and culminating with keratinization of the ocular surface, along with corneal limbal stem cell deficiency associated with corneal ulcer formation, all as a result of the prolonged status of inflammation (Tsai et al., 1995 and Foster et al., 1982). [0016]
  • A recent clinical report describes the effects of amniotic membrane transplantation in the mid-late stage (II-IV) of OCP patients. This surgical approach is considered a strategy to restore the anterior ocular surface anatomy, to maintain the fornix depth, and to reduce conjunctival inflammation (Barabino et al., 2003). Even if OCP patients may benefit from the use of multi-layer amniotic membrane transplantation, the beneficial effect of this therapy is frequently transient, and low final visual acuity is often observed. It has not yet been explained if the increasing effectiveness of multi-layer amniotic membrane transplantation is related to an increase in the mechanical support to the affected tissue or due to the higher amount of factors released by the multi-layered amniotic membranes. It is also not understood why multiple applications of amniotic membranes still are not able to completely manage the disease. A plausible explanation may be related to the biphasic course of OCP, i.e., an immediate conjunctival immune reaction, plus the changes due to this inflammation, that, when they begin, are rendered irreversible by a cascade of effects. Early diagnosis and treatment is then crucial. [0017]
  • In an experiment described herein, use of the composition of the invention blocked OCP progression in a human patient. The OCP was monolateral and at a relatively early stage. Treatment according to the method of the invention did not include surgery and resulted in a stable outcome. These findings suggest that treatment with amniotic membrane extract in accordance with the invention is highly effective in OCP early stage. [0018]
  • In addition, based on the present findings, treatment with the composition according to the invention should be considered in many anterior ocular surface conditions (see infra), whether they have immunological involvement or not, in which amniotic membrane transplantation currently shows limited effects, including lids and conjunctival inflammation associated with deep corneal ulcers. [0019]
  • Accordingly, in one aspect, the invention is directed to a novel extract of amniotic membrane for treating, e.g., visual system and other organ injuries or diseases. Exemplary visual system injuries or diseases that the therapeutic composition of the invention may be used to treat are as follows: for the reconstruction of the ocular surface in patients with limbal stem cells deficiency (Tseng et al., 1998); for the treatment of visual system age-related diseases in general; for reconstruction of the ocular surface in patient with corneal persistent epithelial defect (Tseng et al., 1998); for corneal epithelial healing and to avoid corneal stromal remodeling and haze formation after photorefractive keratectomy (Woo et al., 2001); as a substance that can promote and support healing processes following ocular surface damage related to Stevens Johnson Syndrome and OCP (Tsubota et al., 1996); for healing support and a therapeutic approach in other eye anterior surface diseases including dry eye, Sjögren's syndrome, thermal and chemical burns, and acute and chronic inflammation; and as a versatile compound that can treat the causes of total and partial epithelial stem cells deficiency. Exemplary total epithelial stem cell deficiencies include, but are not limited to, chemical and thermal injuries, Stevens Johnson Syndrome, multi-surgery effects in the limbal region, contact lens over-wear and severe microbial infections. Exemplary partial epithelial stem cell deficiency include, but are not limited to, neurotrophic keratitis, ischemic keratitis, peripheral ulcerative and inflammatory keratitis, limbitis, aniridia, pterigium, pseudopterigium and multiple endocrine deficiency (Tseng et al., 1998; Uchida et al., 2000). [0020]
  • Other exemplary uses of the composition according to the invention are as a treatment for skin dystrophies, burn injury and skin ulcers (Trelford et al., 1979); as a therapy for chemiotheraphic stomatitis; as an immunomodulator in autoimmune disease; to increase tolerance in the treatment of auto-, allo- and xeno-transplants; as an osteoinductive property substance for guided bone regeneration (Gomes et al., 2001); as a substance that can be incorporated in the actual hardware currently used for bacterial and other simple organism culture in vitro or in vivo; as a substance that can be incorporated in currently used devices dedicated to cell culture, such as cell culture dishes, a three-dimensional matrix or a gel (Uchida et al., 2000); as a storage or culture medium for human cells; as a part of an integrated delivery system that will transport the effective compound from an accessible site to the site in need, for remote release of all the beneficial effects of the amniotic membrane; as a bone and tissue anti-inflammatory drug; as a source of factors and receptors for used in neuro-degenerative or inflammatory diseases; and as a source of receptors that mediate glucose transport. [0021]
  • The amniotic membrane extract according to the invention comprises all of the cytokines in a fresh amniotic membrane, e.g., growth factors, receptors and molecules necessary for, e.g., wound healing and other effects. The term “cytokines” includes, but is not limited to, growth factors, interleukins, interferons and colony stimulating factors. Growth factors include, but are not limited to, epidermal growth factor, fibroblast growth factor, nerve growth factor, mast cell-stimulating growth factor and Schwann cell growth factor. These factors are present in normal tissue at different stages of tissue development, marked by cell division, morphogenesis and differentiation. Among these factors are stimulatory molecules that provide the signals needed for in vivo tissue repair. These cytokines can stimulate repair of injured tissue. [0022]
  • In one aspect, the amniotic membrane extract of the invention can be in the form of a powder, where the homogenated amniotic membranes have been lyophilized to dryness. Samples of a frozen homogenate can be processed in a lyophilizer to remove all the water content from the homogenate and to form a powder. The lyophilized powder should be stored at least under refrigeration (4° C.) and preferably at −20° C. The powder can be transported where needed and reconstituted gently (e.g., preferably without shaking or stirring, at 4° C.), protected from light and under sterile conditions at neutral pH, e.g., in balanced salt solution (or other carriers such as gels, ointments, creams, soaps, suspensions, membranes, 3D matrix, delivery systems, biological carriers, etc.) before use. At least four hours should be allowed for the powder to dissolve or be dispersed in the delivery medium. The extract according to the invention also can be reconstituted, or diluted, if desired, with fresh amniotic fluid, autologous serum from a prospective patient or other liquid medium. [0023]
  • In yet another aspect of the invention, the therapeutic composition can be used as an ingredient in cosmetics, to improve wound healing, for example, for patients affected by facial dermabrasion and other skin dystrophies (Kucan, 1982). Other exemplary cosmetic uses may include, but are not limited to, moisturizing and treating dry and sensitive skin, providing anti-aging effects and improving the health of hair roots. The amniotic membrane composition according to the invention may also be used, e.g., as an anti-wrinkle, anti-aging moisturizer; in eczematoid skin conditions; in psoriasis vulgaris skin conditions; in acne vulgaris skin condition; in unspecified or idosyncratic inflammatory skin conditions; and as a compound to hydrate and moisturize pressure ulcers, diabetic ulcers, ischemic ulcers, and any other kind of dystrophic ulcers. [0024]
  • The therapeutic compositions of the invention may be administered topically or by routine methods in pharmaceutically acceptable inert carrier substances. For example, the compositions of the invention may be administered in a sustained release formulation using a biodegradable biocompatible polymer, or by on-site delivery using micelles, gels, ointments or liposomes. For example, for skin disorders or for cosmetic purposes, the amniotic membrane composition of the invention may be administered in a spreadable ointment. The human amniotic membrane extract of the invention can be administered in different dosages as described below (e.g., several times per day at an amount from 1 μg to 1 mg amniotic membrane tissue equivalents per administration), as appropriate. Optimal dosage and modes of administration can readily be determined by conventional protocols. [0025]
  • The therapeutic compositions of the invention can be administered independently or co-administered with another agent as desirable. For example, an extract of another vital organ such as the placenta could also be included. It is contemplated that the therapeutic compositions of the invention will be particularly useful for ocular diseases and conditions, for example, when administered in preservative-free eye drops containing an antibacterial agent. [0026]
  • The therapeutic compositions of the invention can also be prepared as a kit for the curative or prophylactic treatment of disease with instructions for use thereof. The kit of the invention may comprise the amniotic membrane extract in powder form or provided in a saline solution in a pharmaceutically acceptable carrier vehicle, or incorporated in different carriers, media or matrices. [0027]
  • The contents of all references, pending patent applications and published patent applications, cited throughout this application are hereby incorporated by reference. [0028]
  • The following examples are presented to illustrate the advantages of the present invention and to assist one of ordinary skill in making and using the same. These examples are not intended in any way otherwise to limit the scope of the disclosure. [0029]
  • EXAMPLE I Preparation of the Amniotic Membrane Extract
  • In an exemplary isolation procedure, the amniotic membrane was removed from a pregnant woman in the operating room, at the moment of Caesarian parturition, dissected from the other tissues of the placenta and rinsed in a sterile solution, e.g., phosphate-buffered saline (PBS) as described by Kim et al., 1995. Sections of the amniotic membrane were divided into one cm square pieces under sterile conditions and stored at 4° C. in PBS containing 1000 U/ml penicillin and 20 mg/ml streptomycin until processing. [0030]
  • The following procedures were all carried out at 4° C. and neutral pH (approximately 7.4) under sterile conditions and with protection from direct light: Amniotic membrane pieces were weighed and the volume was adjusted to reach a ratio of the g of amniotic membrane/ml of neutral buffer solution of approximately 0.3. The membrane pieces were then sonicated using a Branson 250 sonicator with 3 steps of 3 min each at the following conditions: 20% duty cycle, output in micro tip limit 8. After a pH check, the homogenate was centrifuged for 10 minutes at 4° C. and 4000 rpm and then the supernatant centrifuged for another 5 minutes at 14000 rpm to get rid of any undesired residues present in the extract. [0031]
  • After another pH check, an aliquot of the homogenate (supernatant) was analyzed by a protein assay to quantify the total protein amount present in the homogenate. The homogenated sample was then filtered through 0.8 micron filters under a sterile hood, protecting the compound from light and overheating and maintaining the homogenate temperature at 4° C. or below. Aliquots of the sample suspension were quickly frozen in 100% ethanol-dry ice and stored at −80° C. until the lyophilization procedure. The aliquots were then lyophilized for 24 hours at −20° C. in a sterile lyophilizer. [0032]
  • According to the above protocol, the approximate amount of homogenated amniotic membrane tissue per 1 ml of solution before lyophilization was about 300-350 mg. Thus, 1 ml aliquots of homogenate, lyophilized, are equivalent to approximately 300-350 mg of amniotic membrane tissue. (This amount of protein was also confirmed by protein assay after reconstitution.) The lyophilized powder was stored (e.g., at −20° C.) for six months at least so as to allow for the growth of any viruses that might have been present but undetected in the original homogenate preparation. Any reconstituted samples testing positive for the presence of viruses will be destroyed. [0033]
  • Lyophilized homogenate was then reconstituted gently at 4° C. and neutral pH, under sterile conditions and protected from light, in an appropriate vehicle and at an appropriate concentration for the intended use. For the high concentrations used at the start of the treatment protocol of Example II, the lyophilized homogenate was reconstituted at approximately 8 mg amniotic tissue equivalents/ml balanced salt solution (BSS). Before use, a sample of the reconstituted stock was re-tested for the presence of any viruses. [0034]
  • EXAMPLE II Treatment of an Ocular Condition in a Human Patient
  • A patient who developed Ocular Cicatritial Pemphigoid (OCP) and who had refused many available treatments was successfully treated with the novel composition of the invention. The treatment was for a short period of time, but this treatment was able to stabilize the patient's clinical condition even after use of the amniotic membrane composition was discontinued. [0035]
  • In July 2001, a 57 year old female patient was identified with a history of asymmetric intense burning-like pain, foreign body sensation, photophobia, epiphora and mucous discharge with a severely low visual acuity in the right eye (able to see hand movements). She had an absence of corneal sensitivity (established looking for a change in Cochet-Bonnet esthesiometer reading), a chronic corneal ulcer extended to the limbus (FIGS. 1A and 1B, day 0) and inferior fornix foreshortening with trichiasis but not entropion. She had had previous episodes of conjunctival inflammation followed by inferior lids conjunctiva progressive scars and was diagnosed clinically and histologically as having OCP (showing linear deposition of IgG in the basement membrane) . According to the Foster et al. (1982) OCP classification, the patient was compatible with late stage 2 to early stage 3. Her treatment history had included tear substitutes, soft contact lenses and anti-inflammatory drugs. She refused any topical corticosteroids or immunosuppressive agents in combination with short-term steroids or minor surgical procedures. The therapies previously mentioned, including midriatic agents, were able to provide relief for only a short period of time. The conjunctival inflammation did not resolve, and the persistent corneal epithelial defect became chronic. Low visual acuity (e.g., the ability to count a clinician's fingers) was also observed. [0036]
  • The patient's case was managed with the amniotic membrane composition according to the invention in association with other preservative-free eye drops. During the first week of treatment, the treatment protocol included the composition of the invention in high doses (1-2 drops in the affected eye of a composition consisting of 8 mg amniotic membrane tissue equivalents/ml BSS) 5 times a day and with a preservative-free antibiotic (e.g., netilmicina sulfate) 3 times a day, preservative-free artificial tears (e.g., Carbossilmetil-cellulose) 8 times a day and preservative-free Carbomer gel at bedtime. The preservative-free drops were used to prevent bacterial growth and to promote the growth of healing cells. The second and third week of treatment consisted of the composition of the invention at a medium dose (1-2 drops in the affected eye of a composition consisting of 4 mg amniotic membrane tissue equivalents/ml BSS) 3 times a day, preservative-free netilmicina sulfate 2 times a day, preservative-free artificial tears (Carbossilmetil-cellulose) 8 times a day and preservative-free Carbomer gel at bedtime. In the fourth and fifth weeks, treatment consisted of the composition of the invention 3 times a day at a low dose (1-2 drops in the affected eye of a composition consisting of 0.4 mg amniotic membrane tissue equivalents/ml BSS) preservative-free netilmicina sulfate 2 times a day, preservative-free artificial tears (Carbossilmetil-cellulose) 8 times a day and preservative-free Carbomer gel at bedtime. Starting in the sixth week, the use of the amniotic membrane composition was suspended, keeping preservative-free artificial tears (Carbossilmetil-cellulose) treatment every hour in association with soft contact lenses. [0037]
  • From the very beginning of this therapeutic regimen, the patient began to feel less pain. After a transient limbal and conjunctival inflammation, the pain disappeared totally within 2 weeks along with the burning-like pain, the photophobia and, less rapidly, the conjunctival inflammation previously described. The chronic corneal ulcer resolved completely (FIGS. 2A and 2B, day 10 and FIGS. [0038] 3A-3C, days 30 and 40, respectively) within 6 weeks. The patient also recovered her corneal sensitivity and visual acuity (20/200). She had no further episodes of conjunctival inflammation or other episodes of inferior fornix foreshortening and trichiasis. These clinical findings still represent the stable condition of the patient.
  • EXAMPLE III Treatment of a Skin Condition in a Human Patient
  • A patient having age-related enhanced wrinkling adjacent to the eye was successfully treated with a composition according to the invention. FIG. 4A shows the wrinkling adjacent to the right eye of the patient at day 0. A 0.35 mg/ml amniotic membrane tissue equivalent preparation in a BSS suspension was administered to the patient's skin in the treatment area at a dosage and frequency of 1-2 drops per day, at bed time. After 14 days, the wrinkling was substantially diminished, as shown in FIG. 4B. [0039]
  • The composition according to the invention has also been tested in a cell culture system at a concentration range of 0.3-30 mg/ml and shown to be highly effective in ensuring the function and survival of the cultured cells. Testing of the inventive composition has also been carried out in a corneal injury (scraping) mouse model with recovery substantially to normal within 14 days in corneal transparency, specularity and reflection. [0040]
  • References [0041]
  • Barabino S et al. Role of amniotic membrane transplantation for conjunctival reconstruction in ocular-cicatricial pemphigoid. Ophthalmol. 2003, 474-480. [0042]
  • Chen H J et al. R T F Pires, S C G Tseng. Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br. J. Ophthalmol. 2000, 84:826-833. [0043]
  • Chikama T et al. Treatment of neurotrophic keratopathy with substance -P- derived peptide (FGLM) and insulin growth factor-1. Lancet 1998, 351:1783-1784. [0044]
  • Donzis P B et al. Management of noninfectious corneal ulcers. Surv. Ophthalmol. 1987, 32:94-110. [0045]
  • Foster C S et al. Immuno-suppresive therapy for progressive ocular cicatricial pemphigoid. Ophthalmol. 1982, 89:340-353. [0046]
  • Foster, C S. Cicatricial pemphigoid. Trans. Am. Ophthalmol. Soc. 1986, 527-663. [0047]
  • Foster, C S et al. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmol. 1982, 340-353. [0048]
  • Gomes M F et al. Int. J. Oral Maxillofac. Implants 2001, 16(4):563-71. [0049]
  • Gould H L. Treatment of neurotrophic keratitis with scleral contact lenses. Eye, Ear, Nose and Throat Monthly 1967, 46:1406-14. [0050]
  • Hosolani H et al. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am. J. Ophthalmol. 1995, 119:288-294. [0051]
  • Hyndiuk R A et al. Neurotrophic corneal ulcers in diabetes mellitus. Arch. Ophthalmol. 1977, 95:2193-6. [0052]
  • Kandarakis A S et al. The effect of epidermal growth factor on epithelial healing after penetrating keratoplasty in human eyes. Am. J. Ophthalmol. 1984, 98:411-415. [0053]
  • Kim J C et al. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. Cornea. 1995, 14:473-484. [0054]
  • Koizumi et al. Curr. Eye Res. 2000, 20:173-7. [0055]
  • Kubo et al. I.O.V.S. 2001, 42:1539-46. [0056]
  • Kuncan J O et al. Amniotic membranes as dressings following facial dermabrasion. Ann. Plast. Surg. 1982, 8:523-7. [0057]
  • Lambiase A et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N. Engl. J. Med. 1998, 338:1174-80. [0058]
  • Sao-Bing Lee et al. Curr. Eye Res. 2000, 20:325-34. [0059]
  • Liesegang T J. Corneal complications from herpes zoster ophthalmicus. Ophthalmol. 1985, 92:316-24. [0060]
  • Prabhasawat P. Single and multilayer amniotic membrane transplantation for persistent corneal epithelial defect with and without stromal thinning and perforation. Br. J. Ophthalmol. 2001, 85:1455-1463. [0061]
  • Saiko U et al. Neurotrophic Function of Conditioned Medium From Human Amniotic Epithelial Cells. J. Neurosci. Res. 2000, 62:585-592. [0062]
  • Solomon A et al. Amniotic Membrane Grafts for non traumatic Corneal Perforations, Descemetoceles, and Deep Ulcers. Ophthalmol. 2002, 109:694-703. [0063]
  • Trelford J D et al. Am. J. Obstet. Gynecol. 1979, 134:833-845. [0064]
  • Tsai R J F et al. Effect of stromal inflammation on the outcome of limbal transplantation for corneal surface reconstruction. Cornea. 1995, 439-449. [0065]
  • Tseng S C G et al. Important concepts for treating ocular surface and tear disorders. Am. J. Ophthalmol. 1997, 124:825-35. [0066]
  • Tseng et al. Arch. Ophthalmol. 1998, 116:431-441. [0067]
  • Tsubota et al. Am. J. Ophthalmol. 1996, 122:38-52. [0068]
  • Uchida et al. J. of Neurosci. Res. 2000, 62:585-590. [0069]
  • Woo et al. Br. J. Ophthalmol. 2001, 85:345-349. [0070]
  • While the present invention has been described in conjunction with a preferred embodiment, one of ordinary skill, after reading the foregoing specification, will be able to effect various changes, substitutions of equivalents, and other alterations to the compositions and methods set forth herein. It is therefore intended that the protection granted by Letters Patent hereon be limited only by the definitions contained in the appended claims and equivalents thereof. [0071]

Claims (17)

What is claimed is:
1. A method of preparing an amniotic membrane extract, said method comprising the steps of:
obtaining a healthy amniotic membrane from a pregnant mammal;
homogenizing said membrane to obtain a homogenate solution;
freezing said homogenate solution; and
lyophilizing said frozen homogenate solution to dryness.
2. The method of claim 1, further comprising the step of processing said lyophilized homogenate to a powder.
3. The method of claim 1, further comprising the step of reconstituting said lyophilized homogenate.
4. The method of claim 3, wherein said lyophilized homogenate is reconstituted in a liquid.
5. The method of claim 4, wherein said liquid is selected from the group consisting of balanced salt solution and fresh amniotic fluid.
6. The method of claim 3, wherein said lyophilized homogenate is reconstituted in a gel, an ointment, a cream or a soap.
7. The method of claim 1, wherein said amniotic membrane is a human amniotic membrane.
8. The method of claim 1, wherein said amniotic membrane is obtained from a mammal selected from the group consisting of pig, cow or horse.
9. The method of claim 1, wherein said amniotic membrane is freshly obtained.
10. A pharmaceutical composition for prophylaxis and/or treatment of a disease or condition, said composition comprising:
a therapeutically effective amount of an amniotic membrane extract prepared according to the method of claim 1; and
a pharmaceutically acceptable carrier for administering said amniotic membrane extract to a patient in need of said prophylaxis and/or treatment.
11. The pharmaceutical composition of claim 10, wherein said pharmaceutically acceptable carrier is selected from the group consisting of an ophthalmic solution for eye drops, a gel, an ointment, an emulsion, a cream, a powder and a spray.
12. The pharmaceutical composition of claim 10, wherein said pharmaceutically acceptable carrier is a bandage or a medicinal contact lens for local administration to said patient.
13. A method of prophylaxis and/or treatment of a disease or condition, said method comprising the steps of:
providing a patient in need of such prophylaxis and/or treatment; and
administering an effective amount of the pharmaceutical composition of claim 11 to said patient.
14. The method of claim 13, wherein said disease or condition is selected from the group consisting of persistent corneal ulcer, Ocular Cicatritial Pemphigoid, Stevens-Johnson syndrome, conjunctival inflammation, dry eye, Sjögren's syndrome, chemical or thermal injuries, multi-surgery effects, contact lenses over-wear, severe microbial infections, neurotrophic keratitis, ischemic keratitis, peripheral ulcerative or inflammatory keratitis, limbitis aniridia, pterigium or pseudopterigium, and multiple endocrine deficiency.
15. The method of claim 13, wherein said carrier in said pharmaceutical composition for said amniotic membrane extract is preservative free eye drops.
16. A kit for prophylaxis and/or treatment of a disease or condition, wherein said kit comprises:
a therapeutically effective amount of an amniotic membrane extract prepared according to the method of claim 1; and
instructions for the use thereof.
17. The kit of claim 16, said kit further comprising a pharmaceutically acceptable carrier for administering said amniotic membrane extract to a patient in need of said prophylaxis and/or treatment.
US10/665,188 2002-09-18 2003-09-17 Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin Abandoned US20040057938A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US41173802P true 2002-09-18 2002-09-18
US10/665,188 US20040057938A1 (en) 2002-09-18 2003-09-17 Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/665,188 US20040057938A1 (en) 2002-09-18 2003-09-17 Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin
US11/977,659 US7871646B2 (en) 2002-09-18 2007-10-25 Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin
US13/956,520 US8738494B1 (en) 2003-09-17 2013-08-01 End user generated billing cycles

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/779,646 Continuation US8682790B1 (en) 2003-06-19 2013-02-27 Method for using different billing cycles for point of sale transactions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/487,680 Continuation-In-Part US20060259390A1 (en) 2003-06-19 2006-07-17 Multiple account preset parameter method, apparatus and systems for financial transactions and accounts
US11/977,659 Division US7871646B2 (en) 2002-09-18 2007-10-25 Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin

Publications (1)

Publication Number Publication Date
US20040057938A1 true US20040057938A1 (en) 2004-03-25

Family

ID=32030724

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/665,188 Abandoned US20040057938A1 (en) 2002-09-18 2003-09-17 Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin
US11/977,659 Active US7871646B2 (en) 2002-09-18 2007-10-25 Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/977,659 Active US7871646B2 (en) 2002-09-18 2007-10-25 Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin

Country Status (4)

Country Link
US (2) US20040057938A1 (en)
EP (1) EP1549328A4 (en)
AU (1) AU2003272536A1 (en)
WO (1) WO2004026244A2 (en)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287223A1 (en) * 2004-06-23 2005-12-29 Peyman Gholam A Use of amniotic membrane as biocompatible devices
WO2006094247A2 (en) * 2005-03-02 2006-09-08 Tissuetech, Inc. Amniotic membrane extracts, compositions thereof, and methods of use
WO2007010305A2 (en) * 2005-07-15 2007-01-25 The University Of Nottingham Surgical membrane
US20070071828A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20070071740A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Purified amniotic membrane compositions and methods of use
US20070231297A1 (en) * 2006-03-29 2007-10-04 Smith Charlotte A Methods related to wound healing
US20080046095A1 (en) * 2006-08-17 2008-02-21 Surgical Biologics, Inc. Placental Tissue Grafts and Improved Methods of Preparing and Using the Same
US20080286378A1 (en) * 2005-02-22 2008-11-20 Ashley Behrens Use of Amniotic Fluid (Af) in Treating Ocular Disease and Injury
US20090010899A1 (en) * 2005-03-31 2009-01-08 Palladino Linda O Methods related to surgery
US20100104539A1 (en) * 2007-09-07 2010-04-29 John Daniel Placental tissue grafts and improved methods of preparing and using the same
WO2011031489A2 (en) 2009-08-25 2011-03-17 Tissuetech, Inc. Umbilical cord amniotic membrane products
EP2460875A1 (en) 2005-03-31 2012-06-06 Stemnion, Inc. Amnion-derived cell compositions, methods of making and uses thereof
US20140079688A1 (en) * 2009-12-07 2014-03-20 Stemnion, Inc. Methods for treating ophthalmic disorders, diseases and injuries
US20140255355A1 (en) * 2013-03-07 2014-09-11 Stemnion, Inc. Methods for treating blepharitis
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8932805B1 (en) 2011-10-31 2015-01-13 BioDlogics, LLC Birth tissue material and method of preparation
US20150140114A1 (en) * 2013-11-19 2015-05-21 John R. SASKO Skin treatment protocol utilizing amniotic solution
US20150150915A1 (en) * 2013-12-04 2015-06-04 Stemnion, Inc. Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve
WO2015008166A3 (en) * 2013-07-12 2015-07-30 Casey Patrick J Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
US20160120912A1 (en) * 2014-11-05 2016-05-05 Tissuetech, Inc. Compositions and method for promoting nerve growth and regeneration
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US20160199417A1 (en) * 2014-06-15 2016-07-14 Amnio Technology Llc Method of treatment utilizing an acellular amnion derived therapeutic composition
JP2016529070A (en) * 2013-09-10 2016-09-23 ミメディクス グループ インコーポレイテッド Cosmetic use of molded placenta compositions
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
WO2017062948A1 (en) * 2015-10-09 2017-04-13 Mam Holdings Of West Florida, Llc Amniotic fluid topical formulation for the treatment of eye disorders
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US9795639B1 (en) 2013-03-16 2017-10-24 BioDlogics, LLC Methods for the treatment of erectile dysfunction by human birth tissue material compostion
US9808491B2 (en) 2014-06-03 2017-11-07 Tissuetech, Inc. Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
US9907821B2 (en) 2015-10-09 2018-03-06 MAM Holdings of West Florida, L.L.C. Amniotic fluid formulation for treatment of joint pain or disorders
US9993506B1 (en) 2013-03-16 2018-06-12 BioDlogics, Inc. Methods for the treatment of degenerative disc diseases by human birth tissue material composition
US10016459B1 (en) 2013-03-13 2018-07-10 BioDlogics, LLC Platelet-rich plasma derived from human umbilical cord blood
US10039792B1 (en) * 2013-03-16 2018-08-07 Brahm Holdings, Llc Methods for the treatment of inflammation and pain using human birth tissue material composition
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10201573B1 (en) 2014-10-27 2019-02-12 Brahm Holdings, Llc Human birth tissue material composition and methods for the treatment of damage associated with a cerebral vascular accident
US10265438B1 (en) 2014-11-03 2019-04-23 BioDlogics, LLC Methods and compositions for the repair and replacement of connective tissue
US10342831B2 (en) 2015-05-20 2019-07-09 Tissuetech, Inc. Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
US10363278B2 (en) 2014-06-15 2019-07-30 Amnio Technology Llc Frozen therapeutic dose and package
GB2571623A (en) * 2018-01-19 2019-09-04 Biocel Ltd Compositions and methods relating to amnion
US10485521B2 (en) 2014-10-07 2019-11-26 MAM Holdings of West Florida, L.L.C. Method for obtaining sterile human amniotic fluid and uses thereof

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071135B2 (en) 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
WO2012112410A2 (en) * 2011-02-14 2012-08-23 Mimedx Group Inc. Micronized placental tissue compositions and methods for making and using the same
EP3311826A1 (en) * 2011-02-14 2018-04-25 MiMedx Group, Inc. Micronized placental tissue compositions and methods for making and using the same
US9295753B1 (en) 2012-07-02 2016-03-29 Celso Tello Amniotic membrane preparation and device for use as a lens or as a dressing for promoting healing
US9943551B2 (en) * 2012-08-15 2018-04-17 Mimedx Group, Inc. Tissue grafts composed of micronized placental tissue and methods of making and using the same
WO2014040026A2 (en) * 2012-09-10 2014-03-13 Wake Forest University Health Sciences Amniotic membrane and its use in wound healing and tissue engineering constructs
US9180145B2 (en) 2012-10-12 2015-11-10 Mimedx Group, Inc. Compositions and methods for recruiting and localizing stem cells
US10206977B1 (en) 2013-01-18 2019-02-19 Mimedx Group, Inc. Isolated placental stem cell recruiting factors
JP6545102B2 (en) 2013-01-18 2019-07-17 ミメディクス グループ インコーポレイテッド How to treat a cardiac condition
ITVI20130038A1 (en) * 2013-02-20 2014-08-21 Lega S S R L Method for the preparation of multi-layer material from human amniotic membrane, as well as' use of the material for the treatment of tissue pathologies
US10029030B2 (en) 2013-03-15 2018-07-24 Mimedx Group, Inc. Molded placental tissue compositions and methods of making and using the same
AU2015206236A1 (en) 2014-01-17 2016-07-21 Mimedx Group, Inc. Method for inducing angiogenesis
WO2015195508A1 (en) * 2014-06-15 2015-12-23 Amnio Technology Llc Frozen therapeutic dose and package
US9132156B1 (en) * 2014-06-15 2015-09-15 Amnio Technology Llc Acellular amnion derived therapeutic compositions
US20160287752A1 (en) * 2014-12-31 2016-10-06 Applied Biologics, Llc Reconstituted amniotic membrane-amniotic fluid combination tissue graft with standardized stem cell component and method of forming same
US20160287640A1 (en) * 2014-12-31 2016-10-06 Applied Biologics, Llc Denuded amnion flowable tissue graft and method of forming same
WO2016109828A1 (en) * 2014-12-31 2016-07-07 Applied Biologics, Llc Injectable amniotic membrane tissue graft
WO2016109821A1 (en) * 2014-12-31 2016-07-07 Applied Biologics, Llc Reconstituted amniotic membrane-amniotic fluid combination tissue graft
US9694109B1 (en) * 2015-01-06 2017-07-04 Brahm Holdings, Llc Nanoparticle-containing placental constructs and methods of use
SG11201707539QA (en) 2015-04-10 2017-10-30 Dompe' Farm S P A Method for manufacturing a dispensing device for eye drops
JP2018515178A (en) * 2015-04-10 2018-06-14 ドンペ ファーマスーチシ ソシエタ ペル アチオニ Ophthalmic administration device
US9603967B2 (en) 2015-05-08 2017-03-28 Vivex Biomedical, Inc. Placental tissue assembly
US20170136070A1 (en) * 2015-11-18 2017-05-18 Dregalla Patent Holdco, LLC Acellular Regenerative Products and Methods of Their Manufacture

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002071A (en) * 1987-04-03 1991-03-26 Research Development Foundation Injectable soft tissue augmentation materials from the placenta and their method of manufacture
US5932205A (en) * 1997-07-24 1999-08-03 Wang; Ming X. Biochemical contact lens for treating photoablated corneal tissue
US6117857A (en) * 1995-02-06 2000-09-12 Astra Aktiebolag Pharmaceutical composition
US6143315A (en) * 1997-07-24 2000-11-07 Wang; Ming X. Biochemical contact lens for treating injured corneal tissue
US6326019B1 (en) * 1997-02-28 2001-12-04 Scheffer C. G. Tseng Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2110531B (en) * 1981-11-05 1985-05-01 East Grinstead Research Trust Wound healing composition prepared from amnion
RU2063761C1 (en) * 1991-11-22 1996-07-20 Юрий Геннадьевич Пилипенко Method for obtaining antiinflammatory and immunostimulating substance from placenta
KR20010098716A (en) * 2000-04-19 2001-11-08 정찬복 Amnionic extract for ophthalmopathy
KR100377921B1 (en) * 2000-05-04 2003-03-29 정원태 manufacture method for eye unguent in photorefractive keratectomy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002071A (en) * 1987-04-03 1991-03-26 Research Development Foundation Injectable soft tissue augmentation materials from the placenta and their method of manufacture
US6117857A (en) * 1995-02-06 2000-09-12 Astra Aktiebolag Pharmaceutical composition
US6326019B1 (en) * 1997-02-28 2001-12-04 Scheffer C. G. Tseng Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
US5932205A (en) * 1997-07-24 1999-08-03 Wang; Ming X. Biochemical contact lens for treating photoablated corneal tissue
US6143315A (en) * 1997-07-24 2000-11-07 Wang; Ming X. Biochemical contact lens for treating injured corneal tissue

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287223A1 (en) * 2004-06-23 2005-12-29 Peyman Gholam A Use of amniotic membrane as biocompatible devices
US20080286378A1 (en) * 2005-02-22 2008-11-20 Ashley Behrens Use of Amniotic Fluid (Af) in Treating Ocular Disease and Injury
WO2006094247A2 (en) * 2005-03-02 2006-09-08 Tissuetech, Inc. Amniotic membrane extracts, compositions thereof, and methods of use
WO2006094247A3 (en) * 2005-03-02 2006-10-26 Tissuetech Inc Amniotic membrane extracts, compositions thereof, and methods of use
EP2460875A1 (en) 2005-03-31 2012-06-06 Stemnion, Inc. Amnion-derived cell compositions, methods of making and uses thereof
US8153430B2 (en) 2005-03-31 2012-04-10 Stemnion, Inc. Methods related to surgery
US20090010899A1 (en) * 2005-03-31 2009-01-08 Palladino Linda O Methods related to surgery
US20080193554A1 (en) * 2005-07-15 2008-08-14 The University Of Nottingham Surgical Membrane
GB2441939B (en) * 2005-07-15 2011-03-16 Univ Nottingham Surgical membrane
WO2007010305A3 (en) * 2005-07-15 2008-01-10 Harminder Dua Surgical membrane
WO2007010305A2 (en) * 2005-07-15 2007-01-25 The University Of Nottingham Surgical membrane
GB2441939A (en) * 2005-07-15 2008-03-19 Univ Nottingham Surgical membrane
US8440235B2 (en) 2005-09-27 2013-05-14 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US9161954B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20080299087A1 (en) * 2005-09-27 2008-12-04 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
EP1933852A2 (en) * 2005-09-27 2008-06-25 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US9198939B2 (en) 2005-09-27 2015-12-01 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US9161955B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US20070231401A1 (en) * 2005-09-27 2007-10-04 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US10272119B2 (en) 2005-09-27 2019-04-30 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
EP1933852B1 (en) * 2005-09-27 2018-12-19 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US20070071740A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Purified amniotic membrane compositions and methods of use
US8153162B2 (en) * 2005-09-27 2012-04-10 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US8182841B2 (en) * 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US8182840B2 (en) * 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
EP2664337A1 (en) * 2005-09-27 2013-11-20 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) * 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20070071828A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8460714B2 (en) 2005-09-27 2013-06-11 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US9956252B2 (en) 2005-09-27 2018-05-01 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US9750771B2 (en) 2005-09-27 2017-09-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US9750772B2 (en) 2005-09-27 2017-09-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8455009B2 (en) 2005-09-27 2013-06-04 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US9724370B2 (en) 2005-09-27 2017-08-08 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US8420126B2 (en) 2005-09-27 2013-04-16 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US9161956B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US8796025B2 (en) 2006-03-29 2014-08-05 Stemnion, Inc. Methods Related to Wound Healing
US20070231297A1 (en) * 2006-03-29 2007-10-04 Smith Charlotte A Methods related to wound healing
US8871198B2 (en) 2006-03-29 2014-10-28 Stemnion, Inc. Methods related to wound healing
US20100080779A1 (en) * 2006-03-29 2010-04-01 Smith Charlotte A Methods related to wound healing
US8187881B2 (en) 2006-03-29 2012-05-29 Stemnion, Inc. Methods related to wound healing
US8372437B2 (en) 2006-08-17 2013-02-12 Mimedx Group, Inc. Placental tissue grafts
US8623421B2 (en) 2006-08-17 2014-01-07 Mimedx Group, Inc. Placental graft
US9572839B2 (en) 2006-08-17 2017-02-21 Mimedx Group, Inc. Placental tissue grafts and methods of preparing and using the same
US9463207B2 (en) 2006-08-17 2016-10-11 Mimedx Group, Inc. Placental tissue grafts
US9433647B2 (en) 2006-08-17 2016-09-06 Mimedx Group, Inc. Placental tissue grafts
US9265801B2 (en) 2006-08-17 2016-02-23 Mimedx Group, Inc. Placental tissue grafts
US9265800B2 (en) 2006-08-17 2016-02-23 Mimedx Group, Inc. Placental tissue grafts
US10406259B2 (en) 2006-08-17 2019-09-10 Mimedx Group, Inc. Placental tissue grafts and improved methods of preparing and using the same
US8597687B2 (en) 2006-08-17 2013-12-03 Mimedx Group, Inc. Methods for determining the orientation of a tissue graft
US8460715B2 (en) 2006-08-17 2013-06-11 Mimedx Group, Inc. Placental tissue grafts
US8460716B2 (en) 2006-08-17 2013-06-11 Mimedx Group, Inc. Method for applying a label to a placental tissue graft
US9956253B2 (en) 2006-08-17 2018-05-01 Mimedx Group, Inc. Placental tissue grafts
US20080046095A1 (en) * 2006-08-17 2008-02-21 Surgical Biologics, Inc. Placental Tissue Grafts and Improved Methods of Preparing and Using the Same
US8709494B2 (en) 2006-08-17 2014-04-29 Mimedx Group, Inc. Placental tissue grafts
US9272005B2 (en) 2006-08-17 2016-03-01 Mimedx Group, Inc. Placental tissue grafts
US9415074B2 (en) 2007-09-07 2016-08-16 Mimedx Group, Inc. Placental tissue grafts
US9084767B2 (en) 2007-09-07 2015-07-21 Mimedx Group, Inc. Placental tissue grafts and methods of preparing and using the same
US8372438B2 (en) 2007-09-07 2013-02-12 Mimedx Group, Inc. Method for inhibiting adhesion formation using an improved placental tissue graft
US20100104539A1 (en) * 2007-09-07 2010-04-29 John Daniel Placental tissue grafts and improved methods of preparing and using the same
US8372439B2 (en) 2007-09-07 2013-02-12 Mimedx Group, Inc. Method for treating a wound using improved placental tissue graft
US8409626B2 (en) 2007-09-07 2013-04-02 Mimedx Group, Inc. Placental tissue grafts
US8323701B2 (en) 2007-09-07 2012-12-04 Mimedx Group, Inc. Placental tissue grafts
US8642092B2 (en) 2007-09-07 2014-02-04 Mimedx Group, Inc. Placental tissue grafts
US8709493B2 (en) 2007-09-07 2014-04-29 Mimedx Group, Inc. Placental tissue grafts
US8703207B2 (en) 2007-09-07 2014-04-22 Mimedx Group, Inc. Placental tissue grafts
US9272003B2 (en) 2007-09-07 2016-03-01 Mimedx Group, Inc. Placental tissue grafts
US8932643B2 (en) 2007-09-07 2015-01-13 Mimedx Group, Inc. Placental tissue grafts
US9533011B2 (en) 2007-09-07 2017-01-03 Mimedx Group, Inc. Placental tissue grafts and methods of preparing and using the same
US8703206B2 (en) 2007-09-07 2014-04-22 Mimedx Group, Inc. Placental tissue grafts
US8357403B2 (en) 2007-09-07 2013-01-22 Mimedx Group, Inc. Placental tissue grafts
US9789137B2 (en) 2007-09-07 2017-10-17 Mimedx Group, Inc. Placental tissue grafts and improved methods of preparing and using the same
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
WO2011031489A3 (en) * 2009-08-25 2011-07-21 Tissuetech, Inc. Umbilical cord amniotic membrane products
WO2011031489A2 (en) 2009-08-25 2011-03-17 Tissuetech, Inc. Umbilical cord amniotic membrane products
EP3061468A1 (en) * 2009-08-25 2016-08-31 Tissue Tech, Inc. Umbilical cord amniotic membrane products
US20140079688A1 (en) * 2009-12-07 2014-03-20 Stemnion, Inc. Methods for treating ophthalmic disorders, diseases and injuries
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9675733B2 (en) 2011-04-28 2017-06-13 Tissuetech, Inc. Methods of modulating bone remodeling
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US10426731B2 (en) 2011-06-10 2019-10-01 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US8932805B1 (en) 2011-10-31 2015-01-13 BioDlogics, LLC Birth tissue material and method of preparation
US10245349B2 (en) 2011-10-31 2019-04-02 BioDlogics, LLC Birth tissue material and method of preparation
US20140255355A1 (en) * 2013-03-07 2014-09-11 Stemnion, Inc. Methods for treating blepharitis
US10016459B1 (en) 2013-03-13 2018-07-10 BioDlogics, LLC Platelet-rich plasma derived from human umbilical cord blood
US10039792B1 (en) * 2013-03-16 2018-08-07 Brahm Holdings, Llc Methods for the treatment of inflammation and pain using human birth tissue material composition
US9795639B1 (en) 2013-03-16 2017-10-24 BioDlogics, LLC Methods for the treatment of erectile dysfunction by human birth tissue material compostion
US9993506B1 (en) 2013-03-16 2018-06-12 BioDlogics, Inc. Methods for the treatment of degenerative disc diseases by human birth tissue material composition
WO2015008166A3 (en) * 2013-07-12 2015-07-30 Casey Patrick J Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment
JP2016529070A (en) * 2013-09-10 2016-09-23 ミメディクス グループ インコーポレイテッド Cosmetic use of molded placenta compositions
US20150140114A1 (en) * 2013-11-19 2015-05-21 John R. SASKO Skin treatment protocol utilizing amniotic solution
US20150150915A1 (en) * 2013-12-04 2015-06-04 Stemnion, Inc. Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve
US9636364B2 (en) * 2013-12-04 2017-05-02 Stemnion, Inc. Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve
US9808491B2 (en) 2014-06-03 2017-11-07 Tissuetech, Inc. Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
US10363278B2 (en) 2014-06-15 2019-07-30 Amnio Technology Llc Frozen therapeutic dose and package
US20160199417A1 (en) * 2014-06-15 2016-07-14 Amnio Technology Llc Method of treatment utilizing an acellular amnion derived therapeutic composition
US9814746B2 (en) * 2014-06-15 2017-11-14 Amnio Technology Llc Method of treatment utilizing an acellular amnion derived therapeutic composition
US10485521B2 (en) 2014-10-07 2019-11-26 MAM Holdings of West Florida, L.L.C. Method for obtaining sterile human amniotic fluid and uses thereof
US10201573B1 (en) 2014-10-27 2019-02-12 Brahm Holdings, Llc Human birth tissue material composition and methods for the treatment of damage associated with a cerebral vascular accident
US10265438B1 (en) 2014-11-03 2019-04-23 BioDlogics, LLC Methods and compositions for the repair and replacement of connective tissue
US20160120912A1 (en) * 2014-11-05 2016-05-05 Tissuetech, Inc. Compositions and method for promoting nerve growth and regeneration
US10342831B2 (en) 2015-05-20 2019-07-09 Tissuetech, Inc. Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
WO2017062948A1 (en) * 2015-10-09 2017-04-13 Mam Holdings Of West Florida, Llc Amniotic fluid topical formulation for the treatment of eye disorders
US9907821B2 (en) 2015-10-09 2018-03-06 MAM Holdings of West Florida, L.L.C. Amniotic fluid formulation for treatment of joint pain or disorders
GB2571623A (en) * 2018-01-19 2019-09-04 Biocel Ltd Compositions and methods relating to amnion

Also Published As

Publication number Publication date
US20080108045A1 (en) 2008-05-08
AU2003272536A8 (en) 2004-04-08
EP1549328A2 (en) 2005-07-06
US7871646B2 (en) 2011-01-18
AU2003272536A1 (en) 2004-04-08
EP1549328A4 (en) 2009-07-08
WO2004026244A2 (en) 2004-04-01
WO2004026244A3 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
Shimazaki et al. Transplantation of human limbal epithelium cultivated on amniotic membrane for the treatment of severe ocular surface disorders
US8449879B2 (en) Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
CA2623940C (en) Amniotic membrane preparations and purified compositions and methods of use
US10213405B2 (en) Ophthalmic compositions and methods for treating eyes
Calonge The treatment of dry eye
Frucht-Pery et al. Conjunctival autografting combined with low-dose mitomycin C for prevention of primary pterygium recurrence
US9161954B2 (en) Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
Quinto et al. Autologous serum for ocular surface diseases
CA2771908C (en) Umbilical cord amniotic membrane products
CA1254510A (en) Fibronectin preparations
KR100268660B1 (en) Compositon for the treatment of interstitial cystitis
US5955436A (en) Use of platelet derived growth factor to enhance wound healing
Wilson Graft failure after penetrating keratoplasty
Hanada et al. Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera
Malhotra et al. Human amniotic membrane transplantation: different modalities of its use in ophthalmology
King Jr Keratoplasty: Experimental studies with corneas preserved by dehydration
Coster et al. Surgical management of ocular surface disorders using conjunctival and stem cell allografts.
Kobayashi et al. Temporary amniotic membrane patching for acute chemical burns
JPH08259604A (en) Pharmacologically active fraction of hyaluronic acid, its preparation and pharmaceutical composition
US20130156863A1 (en) Methods of preparing chorion tissue and products derived therefrom
HUT65755A (en) Process for production of preparations containing plasminogen-activators for treatment of inflammation and wound
Baradaran-Rafii et al. Amniotic membrane transplantation
Baum Infections of the eye
HU195523B (en) Process for producing fractions of hyaluronic acid and pharmaceutical compositions containing them
WO1998053806A1 (en) Medicinal compositions for topical administration containing vitamin d and vitamin k

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION